First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC - Summary - MDSpire
From the Journals
Clinical Guidelines

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

In a phase IA to IB trial reported in The New England Journal of Medicine, Heymach et al found that first-line zongertinib was active in patients with advanced or metastatic HER2-mutant non–small cell...

Share

A phase IA to IB trial published in The New England Journal of Medicine by Heymach et al. evaluated the efficacy of zongertinib in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC). This oral tyrosine kinase inhibitor selectively targets HER2 while sparing wild-type EGFR, potentially reducing toxicity. In cohort 2 of the study, a 76% objective response rate was observed, with median progression-free survival of 14.4 months. Low-grade adverse events were prevalent, indicating zongertinib's promising profile for treatment.

Original Source(s)

First-Line Zongertinib in Advanced <em>HER2</em>-Mutant NSCLC

  • by Matthew Stenger

  • April 22, 2026

Related Content

CD40 Overexpression Emerges as a Potential Biomarker for Angioimmunoblastic T-Cell Lymphoma

Researchers at The University of Texas MD Anderson Cancer Center have identified CD40 overexpression as a potential prognostic biomarker for angioimmunoblastic T-cell lymphoma, a rare subtype of non-H...

Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases

In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed...

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min